RESUMO
The potential association between hygienic conditions in the environment of lactating cows and the presence of gliotoxinogenic Aspergillus fumigatus strains was studied. Milk samples (individual cow's milk [ICM], bulk tank milk [BTM]) from 44 dairy farms were sampled. In ICM samples, eight different species of Aspergillus were identified. A. flavus and A. fumigatus were predominant, with 37.8% and 26.1% relative densities, respectively. A. fumigatus strains were isolated from 61.4% of the BTM samples, and 34% of these strains were able to produce gliotoxin. Principal component analysis was used to associate the presence of A. fumigatus with some hygienic and sanitary practices. A significant and positive correlation was observed between dry cow therapy and forestripping. The presence of A. fumigatus gliotoxin producers in milk was associated with high somatic cells count (SCC) samples. Good hygienic and sanitary practices were associated with absence of A. fumigatus and relatively low SCCs of <250,000 cells/ml. In general, a high percentage of dairy farms were positive for A. fumigatus in BTM samples. This is the first work that indicates the positive effects of adequate hygienic and sanitary practices in dairy herds on the control of A. fumigatus and related species. By reducing the frequency of Aspergillus spp. in the dairy environment, the risk of farm handlers' exposure and the risk of intramammary fungal infections would also be reduced.
Assuntos
Aspergillus fumigatus/isolamento & purificação , Aspergillus fumigatus/metabolismo , Microbiologia Ambiental , Gliotoxina/metabolismo , Leite/microbiologia , Animais , Animais Domésticos , Bovinos , Leite/citologiaRESUMO
The aim was to carry out a survey of aflatoxin M(1) (AFM(1)) in raw whole milk from bulk tanks. The sample collection was performed in farms located in one the most important milk-production zones in the centre of Argentina. A total of 94 samples of milk from 47 dairy farms were analysed. AFM(1) analysis involved the use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) with prior purification of the extracts using immunoaffinity columns. AFM(1) incidence in raw milk was high as 63.8% and levels were between not detected to 0.07 microg l(-1). Several contaminated samples (39%) were over the European Commission limit for infant milk (0.025 microg l(-1)), although none of samples were above Argentine legislation. Estimates of AFM(1) intake were assessed for different age populations. The average AFM(1) estimated daily intakes were 1.6, 0.5, 0.17 ng kg(-1) body weight day(-1) for 4-year-old babies, young children, and adults, respectively. All tested farms used pastures and silages at similar composition. Even though some farms (13) employed high-risk supplementary feeds, such as peanut pod and/or cotton seed, no statistically significant differences were observed between groups. Information from AFM(1) levels in milk in Argentina is limited. A systematic AFM(1) monitoring programme must be performed by means of accurate and reliable analytical techniques as a strategy for protecting milk consumers.
Assuntos
Aflatoxina M1/química , Contaminação de Alimentos , Leite/química , Adulto , Agricultura , Ração Animal , Animais , Argentina , Peso Corporal , Bovinos , Pré-Escolar , Humanos , LactenteRESUMO
A vaccine was developed against bovine mastitis based on inactivated, highly encapsulated Staphylococcus aureus cells; a crude extract of Staph. aureus exopolysaccharides; and inactivated, unencapsulated Staph, aureus and Streptococcus spp. cells. This vaccine was tested on 30 heifers during a 7-mo period. The 30 heifers were randomly assigned to three groups of 10 heifers each. The prepartum group received two injections of the vaccine at 8 and 4 wk before calving, and the postpartum group received two injections at 1 and 5 wk after calving. The control group received two injections of a placebo at 8 and 4 wk before calving. The vaccine or the placebo was administered subcutaneously in the brachiocephalicus muscle of the neck. The frequencies of intramammary infections caused by Staph. aureus were reduced from 18.8% for heifers in the control group to 6.7 and 6.0% for heifers in the prepartum and postpartum groups, respectively. This protective effect was maintained for at least 6 mo. The relative risk of mastitis caused by Staph. aureus was 0.31 and 0.28 for heifers in the prepartum and postpartum groups, respectively, compared with that for heifers in the control group. The results of the trial indicated the effectiveness of the vaccine in decreasing the incidence of intrammammary infections caused by Staph. aureus. A slight but nonsignificant increase occurred in fat production in the milk of vaccinated cows. The vaccine had no observable effect on somatic cell count or streptococcal infections.
Assuntos
Vacinas Bacterianas , Mastite Bovina/prevenção & controle , Animais , Argentina , Bovinos , Feminino , Lipídeos/biossíntese , Mastite Bovina/microbiologia , Camundongos , Camundongos Endogâmicos BALB C , Leite/metabolismo , Coelhos , Infecções Estafilocócicas/prevenção & controle , Staphylococcus aureus/imunologia , Infecções Estreptocócicas/prevenção & controle , Streptococcus/imunologiaRESUMO
A vaccine against bovine mastitis was developed. The vaccine was based on inactivated, highly encapsulated Staphylococcus aureus cells; a crude extract of Staph. aureus exopolysaccharides; and inactivated unencapsulated Staph. aureus and Streptococcus spp. cells. In this study, the vaccine was evaluated in 164 cows from two commercial dairies (A and B) during a 4-mo period. Two doses of the vaccine were administered subcutaneously to 82 cows in the brachiocephalicus muscle of the neck within a 4-wk interval. The results of this trial revealed significantly fewer intramammary infections caused by Staph. aureus at various levels of severity (clinical, subclinical, and latent) in cows that were vaccinated. The odds ratios of all types of intrammammary infections caused by Staph. aureus for dairies A and B, which were determined by a logistic model, were 1.84 and 1.89, respectively, for quarters of vaccinated cows and quarters of control cows. The colony counts for Staph. aureus in milk from infected quarters of vaccinated cows were significantly lower than those in milk from infected quarters of control cows. Also, the somatic cell counts per milliliter in milk from vaccinated cows were significantly decreased when the initial somatic cell count was < 500,000 cells/ml at the start of the trial. The vaccine had no observable effect on fat production in milk or on streptococcal infections.